Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Johnson and Johnson

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drug Sales Trends for RANITIDINE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Payment Methods and Pharmacy Types for RANITIDINE (2017)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $17,546,686
INSIDE ANOTHER STORE $51,037,410
[disabled in preview] $270,990,451
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 1,032,623
INSIDE ANOTHER STORE 3,398,113
[disabled in preview] 10,908,264
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $77,465,943
MEDICARE $87,318,631
[disabled in preview] $174,789,971
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for RANITIDINE
Drug Units Sold Trends for RANITIDINE

Annual Sales Revenues and Units Sold for RANITIDINE

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
RANITIDINE   Start Trial   Start Trial 2017
RANITIDINE   Start Trial   Start Trial 2016
RANITIDINE   Start Trial   Start Trial 2015
RANITIDINE   Start Trial   Start Trial 2014
RANITIDINE   Start Trial   Start Trial 2013
RANITIDINE   Start Trial   Start Trial 2012
RANITIDINE   Start Trial   Start Trial 2011
>Drug Name >Revenues (USD) >Units >Year

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Baxter
Dow
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
 NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews